The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization
Abstract
BACKGROUND: The objective of this study was to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) as a local salvage treatment after incomplete transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC). METHODS: The main eligibility criteria were a greatest tumor dimension (LD sum) <10 cm, inoperable HCC, and incomplete response after TACE. Prescribed SBRT doses were up to 60 gray (Gy) in 3 fractions, but doses were reduced until normal tissue constraints were allowed. RESULTS: Between May 2008 and February 2011, 50 patients were enrolled in this phase 2 trial, of which 47 patients were evaluable. Forty‐one patients had Child‐Pugh class A disease (A5/A6 were 32/9), 6 patients had class B7 disease, and 5 patients had portal vein tumor thrombosis. All patients underwent TACE 1 to 5 times before SBRT. SBRT doses ranged from 42 to 60 Gy in 3 fractions (median dose, 57 Gy), and the median LD sum was 29 mm (range, 13‐78 mm). Eighteen patients (38.3%) achieved complete remission within 6 months of completing of SBRT, and 18 patients (38.3%) had a partial response. The 2‐year local control rate was 94.6%, the overall survival rate was 68.7%, and the progression‐free survival rate was 33.8%. Three patients (6.4%) experienced grade 3 gastrointestinal toxicity, and 2 patients (4.3%) experienced grade 4 gastric ulcer perforation. CONCLUSIONS: This trial demonstrated that SBRT after incomplete TACE for inoperable HCC achieves promising rates of response and local control. On the basis of these study results, a modified, multi‐institutional, phase 2 trial to reduce gastrointestinal toxicity is recommended. Cancer 2012. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., Pugh, T. J., Kane, M., Gaspar, L. E., & Schefter, T. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6386 · Cited by 1,082
Shiina, S., Teratani, T., Obi, S., Sato, S., Tateishi, R., Fujishima, T., Ishikawa, T., Koike, Y., Yoshida, H., Kawabe, T., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.009 · Cited by 877
Blomgren, H., Lax, I., Näslund, I., & Svanström, R. (1995) · Acta Oncologica · doi:10.3109/02841869509127197 · Cited by 846
Huang, J., Yan, L., Cheng, Z., Wu, H., Du, L., Wang, J., Xu, Y., & Zeng, Y. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181efc656 · Cited by 844
Marelli, L., Stigliano, R., Triantos, C., Senzolo, M., Cholongitas, E., Davies, N., Tibballs, J., Meyer, T., Patch, D. W., & Burroughs, A. K. (2007) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-006-0062-3 · Cited by 791
Arii, S., Yamaoka, Y., Futagawa, S., Inoue, K., Kobayashi, K., Kojiro, M., Makuuchi, M., Nakamura, Y., Okita, K., & Yamada, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20456 · Cited by 725
Cited by
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
Bujold, A., Massey, C. A., Kim, J. J., Brierley, J., Cho, C., Wong, R. K. S., Dinniwell, R. E., Kassam, Z., Ringash, J., Cummings, B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1659 · Cited by 820
Self-citationKorean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
Benson, A. B., D'Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Are, C., Brown, D. B., Chang, D. T., Covey, A. M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0059 · Cited by 345
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 306
Sanuki, N., Takeda, A., Oku, Y., Mizuno, T., Aoki, Y., Eriguchi, T., Iwabuchi, S., & Kunieda, E. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.820342 · Cited by 260
Sheng, H., Huang, Y., Xiao, Y., Zhu, Z., Shen, M., Zhou, P., Guo, Z., Wang, J., Wang, H., Dai, W., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000340 · Cited by 228
Metadata
- Authors
- Kang, J., Kim, M., Cho, C. K., Yang, K. M., Yoo, H. J., Kim, J. H., Bae, S. H., Jung, D. H., Kim, Lee, D. H., Han, C. J., Kim, J., Park, S. C., & Kim, Y. H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-05-08
- Volume
- 118
- Issue
- 21
- Pages
- 5424-5431
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1606647501
- Cited by
- 334
- References
- 18
- FWCI
- 12.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.